Literature DB >> 9499056

In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.

M Lusky1, M Christ, K Rittner, A Dieterle, D Dreyer, B Mourot, H Schultz, F Stoeckel, A Pavirani, M Mehtali.   

Abstract

Isogenic, E3-deleted adenovirus vectors defective in E1, E1 and E2A, or E1 and E4 were generated in complementation cell lines expressing E1, E1 and E2A, or E1 and E4 and characterized in vitro and in vivo. In the absence of complementation, deletion of both E1 and E2A completely abolished expression of early and late viral genes, while deletion of E1 and E4 impaired expression of viral genes, although at a lower level than the E1/E2A deletion. The in vivo persistence of these three types of vectors was monitored in selected strains of mice with viral genomes devoid of transgenes to exclude any interference by immunogenic transgene-encoded products. Our studies showed no significant differences among the vectors in the short-term maintenance and long-term (4-month) persistence of viral DNA in liver and lung cells of immunocompetent and immunodeficient mice. Furthermore, all vectors induced similar antibody responses and comparable levels of adenovirus-specific cytotoxic T lymphocytes. These results suggest that in the absence of transgenes, the progressive deletion of the adenovirus genome does not extend the in vivo persistence of the transduced cells and does not reduce the antivirus immune response. In addition, our data confirm that, in the absence of transgene expression, mouse cellular immunity to viral antigens plays a minor role in the progressive elimination of the virus genome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499056      PMCID: PMC109495          DOI: 10.1128/JVI.72.3.2022-2032.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

Authors:  H Zhou; W O'Neal; N Morral; A L Beaudet
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

2.  Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response.

Authors:  M Christ; M Lusky; F Stoeckel; D Dreyer; A Dieterlé; A I Michou; A Pavirani; M Mehtali
Journal:  Immunol Lett       Date:  1997-06-01       Impact factor: 3.685

3.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

Authors:  S Worgall; G Wolff; E Falck-Pedersen; R G Crystal
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

4.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

Authors:  N Morral; W O'Neal; H Zhou; C Langston; A Beaudet
Journal:  Hum Gene Ther       Date:  1997-07-01       Impact factor: 5.695

5.  Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues.

Authors:  Y Yang; Q Su; I S Grewal; R Schilz; R A Flavell; J M Wilson
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

Authors:  G P Gao; Y Yang; J M Wilson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.

Authors:  P Yeh; J F Dedieu; C Orsini; E Vigne; P Denefle; M Perricaudet
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein.

Authors:  N C Reich; P Sarnow; E Duprey; A J Levine
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

9.  Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro.

Authors:  C A Smith; L S Woodruff; G R Kitchingman; C M Rooney
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor.

Authors:  T Dobner; N Horikoshi; S Rubenwolf; T Shenk
Journal:  Science       Date:  1996-06-07       Impact factor: 47.728

View more
  57 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 4.  Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Authors:  Norbert Avril; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-23       Impact factor: 9.236

5.  Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.

Authors:  Jackie L Stilwell; Douglas M McCarty; Atsuko Negishi; Richard Superfine; R Jude Samulski
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 6.  Progress and problems when considering gene therapy for GSD-II.

Authors:  A Kiang; A Amalfitano
Journal:  Acta Myol       Date:  2007-07

Review 7.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

8.  Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber.

Authors:  V Legrand; D Spehner; Y Schlesinger; N Settelen; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Adenovirus-mediated gene transfer to liver grafts: an improved method to maximize infectivity.

Authors:  S H Chia; D A Geller; M R Kibbe; S C Watkins; J J Fung; T E Starzl; N Murase
Journal:  Transplantation       Date:  1998-12-15       Impact factor: 4.939

10.  Antitumor effect of mSurvivinThr34→Ala in murine colon carcinoma when administered intravenously.

Authors:  Hong-xia Li; Xin-yu Zhao; Lian Wang; Yong-sheng Wang; Bin Kan; Jian-rong Xu; Jiong Li; Yan-Jun Wen; Xing-chen Peng; Xiang Chen; Fei Yan; Bin Ye; Xiao-bo Du; Ju-mei Zhao; Tao Yi; Xian-cheng Chen; Xiao-xia Du; Yu-quan Wei; Xia Zhao
Journal:  Med Oncol       Date:  2009-12-01       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.